Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma

We report the activity and toxicity of docetaxel in 12 evaluable heavily pretreated patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. In all, 42% achieved a partial response, 25% achieved stable disease. Median duration of response was 16 (10–21) weeks. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zekri, J M, Hough, R E, Davies, J M, Molife, R, Hancock, B W, Lorigan, P C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741047/
https://www.ncbi.nlm.nih.gov/pubmed/12778057
http://dx.doi.org/10.1038/sj.bjc.6600914
_version_ 1782171766716628992
author Zekri, J M
Hough, R E
Davies, J M
Molife, R
Hancock, B W
Lorigan, P C
author_facet Zekri, J M
Hough, R E
Davies, J M
Molife, R
Hancock, B W
Lorigan, P C
author_sort Zekri, J M
collection PubMed
description We report the activity and toxicity of docetaxel in 12 evaluable heavily pretreated patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. In all, 42% achieved a partial response, 25% achieved stable disease. Median duration of response was 16 (10–21) weeks. The median overall survival was 70 (9–178) weeks and for responders it was 120 (22–178) weeks. One patient developed one episode of neutropenic sepsis. Docetaxel has limited activity in this group of patients.
format Text
id pubmed-2741047
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-27410472009-09-10 Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma Zekri, J M Hough, R E Davies, J M Molife, R Hancock, B W Lorigan, P C Br J Cancer Clinical We report the activity and toxicity of docetaxel in 12 evaluable heavily pretreated patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. In all, 42% achieved a partial response, 25% achieved stable disease. Median duration of response was 16 (10–21) weeks. The median overall survival was 70 (9–178) weeks and for responders it was 120 (22–178) weeks. One patient developed one episode of neutropenic sepsis. Docetaxel has limited activity in this group of patients. Nature Publishing Group 2003-05-06 2003-04-29 /pmc/articles/PMC2741047/ /pubmed/12778057 http://dx.doi.org/10.1038/sj.bjc.6600914 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical
Zekri, J M
Hough, R E
Davies, J M
Molife, R
Hancock, B W
Lorigan, P C
Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma
title Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma
title_full Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma
title_fullStr Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma
title_full_unstemmed Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma
title_short Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma
title_sort phase ii study of docetaxel in patients with relapsed or refractory malignant lymphoma
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2741047/
https://www.ncbi.nlm.nih.gov/pubmed/12778057
http://dx.doi.org/10.1038/sj.bjc.6600914
work_keys_str_mv AT zekrijm phaseiistudyofdocetaxelinpatientswithrelapsedorrefractorymalignantlymphoma
AT houghre phaseiistudyofdocetaxelinpatientswithrelapsedorrefractorymalignantlymphoma
AT daviesjm phaseiistudyofdocetaxelinpatientswithrelapsedorrefractorymalignantlymphoma
AT molifer phaseiistudyofdocetaxelinpatientswithrelapsedorrefractorymalignantlymphoma
AT hancockbw phaseiistudyofdocetaxelinpatientswithrelapsedorrefractorymalignantlymphoma
AT loriganpc phaseiistudyofdocetaxelinpatientswithrelapsedorrefractorymalignantlymphoma

Ejemplares similares